Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyAnthem Elzonris (tagraxofusp) Coverage Update | Op…
    Ask Trek AI about this page
    CurrentAnthemPolicy CC-0088

    Elzonris (tagraxofusp-erzs) — coverage criteria for BPDCN

    Customize your policy alerts

    Sign up for Anthem Policy CC-0088 alerts

    Get alerted when Policy CC-0088 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Criteria governing medical-benefit coverage and prior authorization for Elzonris (tagraxofusp-erzs) for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), including eligibility, dosing prerequisites, and monitoring requirements for providers and payers.

    Policy Summary
    PayerAnthem
    PolicyElzonris (tagraxofusp-erzs) — coverage criteria for BPDCN
    Policy CodePolicy CC-0088
    Change TypeRevised — wording/formattingprior material change removed ECOG requirement
    Effective Date03/26/2026
    Last ReviewFeb 20, 2026
    Next Review Date
    Key ActionObtain prior authorization and document baseline serum albumin >= 3.2 g/dL and evidence of BPDCN when requesting Elzonris as monotherapy per NCCN 2A.
    SourceLink
    POLICY UPDATE CHANGES

    Updated criteria to reflect NCCN 2A recommendations for place in therapy and removed ECOG score requirement.

    Wording and formatting criteria updates; coding reviewed with no changes.

    53%CLS incidence

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3.2 g/dL
    Baseline albumin
    NCCN 2ACompendia category
    J9269HCPCS

    Coverage and Medical Necessity Criteria

    Approval Criteria

    Requests for Elzonris (tagraxofusp-erzs) may be approved if the following criteria are met:

    Age or Diagnosis: I. Individual is under 19 years of age; OR II. Individual has a diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN)

    Either pediatric age <19 OR diagnosis of BPDCN qualifies to proceed to further criteria

    Place in therapy: III. Using in one of the following ways (NCCN 2A): A. For intensive remission induction therapy; OR B. Treatment until progression if complete response (CR) achieved after induction; OR C. Relapsed/refractory disease, if not already used

    Place in therapy aligned with NCCN 2A

    Monotherapy: IV. Individual is using as monotherapy

    Single-agent use required

    Laboratory prerequisite: V. At initial therapy, individual has a baseline serum albumin of 3.2 g/dL or higher>= 3.2 g/dL

    Per NCCN 2A and product safety guidance

    Requests for Elzonris (tagraxofusp-erzs) will be declined when the specified coverage criteria are not met. Coverage requires that the individual either be <19 years of age or have a diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN), that the drug is used in one of the approved places in therapy (intensive remission induction; treatment until progression if a complete response is achieved after induction; or relapsed/refractory disease if not previously used), that it is administered as monotherapy, and that the individual has a baseline serum albumin of ≥ 3.2 g/dL prior to initial therapy. Requests that do not meet these conditions or that propose Elzonris for other indications will not be approved.

    Elzonris coverage is limited to the scenarios described above. Use of Elzonris for indications other than pediatric patients (<19 years) or for diagnoses other than BPDCN does not meet the criteria. Additionally, coverage is limited to single-agent (monotherapy) use in the specified places in therapy per NCCN 2A (induction, maintenance until progression after CR, or relapsed/refractory if not previously used); combinations or unapproved places in therapy are excluded.

    Covered Regimens and Place in Therapy

    RegimenIndication / Place in TherapyMonotherapy?Baseline albumin requirementCoverage status
    Elzonris (tagraxofusp-erzs) monotherapy per NCCN 2A
    For intensive remission induction therapy; OR treatment until progression if complete response (CR) achieved after induction; OR relapsed/refractory BPDCN (if not previously used)
    Yes — single-agent use required
    Baseline serum albumin ≥ 3.2 g/dL prior to initial therapy
    Covered with criteria

    Billing and Diagnosis Codes

    HCPCSHCPCS
    J9269Injection, tagraxofusp-erzs, 10 micrograms [Elzonris]
    ICD-10 DiagnosisICD-10
    C86.40Blastic NK-cell lymphoma not having achieved remission
    Z51.11Encounter for antineoplastic chemotherapy
    Baseline serum albumin
    Required baseline serum albumin>= 3.2 g/dL prior to initial Elzonris (tagraxofusp-erzs) therapy
    Monitoring frequencyMeasure serum albumin prior to each dose and as clinically indicated during treatment
    Purpose of thresholdMitigates risk of capillary leak syndrome (CLS) and aligns with NCCN 2A and product safety guidance

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Elzonris (tagraxofusp-erzs). Submit a prior authorization request before initiating therapy when the patient is <19 years OR has a diagnosis of BPDCN and will receive Elzonris as monotherapy in an NCCN 2A–recommended place in therapy (induction for intensive remission, treatment until progression if CR achieved after induction, or for relapsed/refractory disease if not previously used).

    • Affected product: Elzonris (tagraxofusp-erzs)
    • Affected population: patients <19 years OR patients with BPDCN using Elzonris as monotherapy per NCCN 2A places in therapy
    Step Therapy

    No Step Therapy Specified

    No step therapy (prior step) requirements are specified beyond the clinical place in therapy and single‑agent (monotherapy) use required per NCCN 2A. There is no requirement to try an alternative agent before Elzonris when the listed coverage criteria are met.

    Definitions and Clinical Terms

    Capillary Leak Syndrome (CLS)
    DefinitionTreatment-emergent Capillary Leak Syndrome (CLS) characterized by hypoalbuminemia, edema, weight gain, hypotension, hepatic injury and potential fatality as reported with Elzonris
    Incidence in trialsOverall incidence 53% (Grade 1–2: 43%; Grade 3: 7%; Grade 4: 1%; 4 fatal events)
    Common features (>=20%)Hepatotoxicity, hypoalbuminemia, edema, weight gain, hypotension
    Relevance to Elzonris therapyBlack box warning for CLS; baseline and on-treatment albumin monitoring and cardiac assessment required
    ECOG Performance Status
    ECOG scale (0–5)0 = fully active; 1 = restricted in strenuous activity; 2 = ambulatory, self-care only; 3 = limited self-care; 4 = completely disabled; 5 = dead

    Background and Drug Information

    Elzonris (tagraxofusp-erzs) is a CD123-directed fusion protein that links interleukin-3 to a truncated diphtheria toxin to target CD123-expressing malignant cells. It is indicated for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive marrow/blood malignancy that often involves skin and lymph nodes and may present as or progress to acute leukemia. The product carries important safety considerations including a risk of capillary leak syndrome and requires baseline and on‑treatment monitoring, including verification of a baseline serum albumin of ≥ 3.2 g/dL prior to initial therapy.

    Policy Summary
    PayerAnthem
    PolicyElzonris (tagraxofusp-erzs) — coverage criteria for BPDCN
    Policy CodePolicy CC-0088
    Change TypeRevised — wording/formattingprior material change removed ECOG requirement
    Effective Date03/26/2026
    Last ReviewFeb 20, 2026
    Next Review Date
    Key ActionObtain prior authorization and document baseline serum albumin >= 3.2 g/dL and evidence of BPDCN when requesting Elzonris as monotherapy per NCCN 2A.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaCovered Regimens and Place in TherapyBilling and Diagnosis CodesProvider Requirements, Prior Authorization, and DocumentationDefinitions and Clinical TermsBackground and Drug Information
    Documentation Required

    Required Documentation

    Document the following in the prior authorization submission: baseline serum albumin (>= 3.2 g/dL), evidence of BPDCN diagnosis (clinical notes, pathology report, or relevant ICD-10 codes), intent and place in therapy per NCCN 2A (induction for intensive remission, treatment until progression if CR achieved after induction, or relapsed/refractory disease if not previously used), and confirmation that Elzonris will be used as monotherapy. Include relevant baseline cardiac assessment and any prior treatments if applicable.

    • Baseline serum albumin value (>= 3.2 g/dL)
    • Documentation of BPDCN diagnosis (pathology report, clinical documentation, or ICD-10)
    • Specify place in therapy/intent per NCCN 2A (induction, maintenance until progression after CR, or relapsed/refractory)
    • Statement that Elzonris will be administered as monotherapy
    • Baseline cardiac assessment and prior treatment history when applicable
    Denial Risk

    Denial Trigger

    Requests will be denied when the listed criteria are not fully met (patient not <19 years and no BPDCN diagnosis; not being used as monotherapy; not used in an NCCN 2A–recommended place in therapy; baseline serum albumin < 3.2 g/dL at initiation). Requests for indications other than those explicitly listed will not be approved.

    ContextUsed to assess functional status and inform treatment decisions
    Policy note on ECOG requirementECOG performance status was provided for clinical context but the ECOG requirement has been removed from criteria (document history reflects removal).